CA3206176A1 - 4-amino-3-(4-phenoxyphenyl)-1,3-dihydro-2h-imidazo[4,5-c]pyridin-2-one derivatives and salts thereof - Google Patents

4-amino-3-(4-phenoxyphenyl)-1,3-dihydro-2h-imidazo[4,5-c]pyridin-2-one derivatives and salts thereof

Info

Publication number
CA3206176A1
CA3206176A1 CA3206176A CA3206176A CA3206176A1 CA 3206176 A1 CA3206176 A1 CA 3206176A1 CA 3206176 A CA3206176 A CA 3206176A CA 3206176 A CA3206176 A CA 3206176A CA 3206176 A1 CA3206176 A1 CA 3206176A1
Authority
CA
Canada
Prior art keywords
compound
formula
salt
pure
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3206176A
Other languages
English (en)
French (fr)
Inventor
Catherine ARABEYRE
Patricia MOLINER
Sabine BOISNARD
Damien SALLABERRY
Serge Perard
Sebastien Roy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genzyme Corp
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of CA3206176A1 publication Critical patent/CA3206176A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CA3206176A 2020-12-23 2021-12-22 4-amino-3-(4-phenoxyphenyl)-1,3-dihydro-2h-imidazo[4,5-c]pyridin-2-one derivatives and salts thereof Pending CA3206176A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063130010P 2020-12-23 2020-12-23
US63/130,010 2020-12-23
US202163245288P 2021-09-17 2021-09-17
US63/245,288 2021-09-17
PCT/US2021/064800 WO2022140511A1 (en) 2020-12-23 2021-12-22 4-amino-3-(4-phenoxyphenyl)-1,3- dihydro-2h-imidazo[4,5-c]pyridin-2-one derivatives and salts thereof

Publications (1)

Publication Number Publication Date
CA3206176A1 true CA3206176A1 (en) 2022-06-30

Family

ID=79730613

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3206176A Pending CA3206176A1 (en) 2020-12-23 2021-12-22 4-amino-3-(4-phenoxyphenyl)-1,3-dihydro-2h-imidazo[4,5-c]pyridin-2-one derivatives and salts thereof

Country Status (12)

Country Link
US (1) US12624030B2 (enExample)
EP (1) EP4267572A1 (enExample)
JP (1) JP2024501247A (enExample)
KR (1) KR20230124663A (enExample)
CN (1) CN116710452B (enExample)
AU (1) AU2021409575B2 (enExample)
CA (1) CA3206176A1 (enExample)
CO (1) CO2023009491A2 (enExample)
IL (1) IL303834A (enExample)
MX (1) MX2023007641A (enExample)
TW (1) TW202241887A (enExample)
WO (1) WO2022140511A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3168146A1 (en) 2020-01-20 2021-07-29 Genzyme Corporation Therapeutic tyrosine kinase inhibitors for relapsing multiple sclerosis (rms)
CA3201936A1 (en) 2020-12-10 2022-06-16 Minhua Chen Crystal form of tolebrutinib and preparation method thereof
IL303834A (en) 2020-12-23 2023-08-01 Genzyme Corp 4-amino-3-(4-phenoxyphenyl)-1,3-dihydro-2H-imidazo[4,5-C]pyridin-2-one derivatives and their salts
EP4540229A1 (en) * 2022-06-14 2025-04-23 Principia Biopharma Inc. Methods of making tolebrutinib
US20260022123A1 (en) * 2022-06-22 2026-01-22 Principia Biopharma Inc. Methods of Making Modified BTK Inhibitors
AU2024214470A1 (en) 2023-02-01 2025-09-11 Principia Biopharma Inc. Methods of diagnosing and treating multiple sclerosis by detecting a biomarker in the cerebrospinal fluid

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3760984A (en) 1971-09-29 1973-09-25 Alza Corp Osmotically powered agent dispensing device with filling means
US3952741A (en) 1975-01-09 1976-04-27 Bend Research Inc. Controlled release delivery system by an osmotic bursting mechanism
WO2003037890A2 (en) 2001-11-01 2003-05-08 Icagen, Inc. Piperidines
CA2485641C (en) 2002-06-06 2010-12-14 Eisai Co., Ltd. Novel condensed imidazole derivatives
US20060045822A1 (en) 2004-09-01 2006-03-02 Board Of Regents, The University Of Texas System Plasma polymerization for encapsulating particles
AU2005284835A1 (en) 2004-09-14 2006-03-23 Novartis Vaccines And Diagnostics Inc. Imidazoquinoline compounds
CA2597587A1 (en) 2005-02-11 2006-08-17 Coley Pharmaceutical Group, Inc. Oxime and hydroxylamine substituted imidazo[4,5-c] ring compounds and methods
US8846697B2 (en) 2006-05-31 2014-09-30 The Regents Of The University Of California Purine analogs
EP2529621B1 (en) 2006-09-22 2016-10-05 Pharmacyclics LLC Inhibitors of bruton's tyrosine kinase
TW200911803A (en) 2007-07-16 2009-03-16 Organon Nv 6-phenyl-1H-imidazo [4,5-c] pyridine-4-carbonitrile derivatives
UY32138A (es) 2008-09-25 2010-04-30 Boehringer Ingelheim Int Amidas sustituidas del ácido 2-(2,6-dicloro-fenilamino)-6-fluoro-1-metil-1h-bencimidazol-5-carboxílico y sus sales farmacéuticamente aceptables
US7741330B1 (en) 2009-10-12 2010-06-22 Pharmacyclics, Inc. Pyrazolo-pyrimidine inhibitors of Bruton's tyrosine kinase
US8940725B2 (en) 2010-05-31 2015-01-27 Ono Pharmaceutical Co., Ltd. Purinone derivative
AU2012255860C1 (en) 2011-05-17 2015-12-10 Principia Biopharma Inc. Tyrosine kinase inhibitors
MX2013013331A (es) 2011-05-17 2014-10-17 Principia Biopharma Inc Derivados de azaindol como inhibidores de tirosina-cinasas.
US9073947B2 (en) 2011-06-10 2015-07-07 Merck Patent Gmbh Compositions and methods for the production of pyrimidine and pyridine compounds with BTK inhibitory activity
BR112014012727B1 (pt) 2011-11-29 2022-10-25 Ono Pharmaceutical Co., Ltd Cloridrato de 6-amino-9-[(3r)-1-(2-butinoil)-3-pirrolidinil]-7-(4-fenoxifenil)-7,9-di-hidro-8h-puri- 8-ona e composição farmacêutica
US8501724B1 (en) 2012-01-31 2013-08-06 Pharmacyclics, Inc. Purinone compounds as kinase inhibitors
MA37711A1 (fr) 2012-06-04 2017-05-31 Pharmacyclics Inc Formes cristallines d'un inhibiteur de tyrosine kinase de bruton
JO3300B1 (ar) 2012-06-06 2018-09-16 Novartis Ag مركبات وتركيبات لتعديل نشاط egfr
CN104487441B (zh) 2012-06-18 2018-06-01 普林斯匹亚生物制药公司 有用于治疗癌症和自身免疫性疾病的可逆的共价吡咯并嘧啶或吡唑并嘧啶
SMT201900344T1 (it) 2012-09-10 2019-07-11 Principia Biopharma Inc Composti di pirazolopirimidina come inibitori di chinasi
CN102942567B (zh) 2012-11-09 2017-02-08 诸城市浩天药业有限公司 吡咯并喹啉醌的二钠盐结晶
KR20150084923A (ko) 2012-11-15 2015-07-22 파마시클릭스, 인코포레이티드 키나제 억제제로서의 피롤로피리미딘 화합물
US20140142099A1 (en) 2012-11-20 2014-05-22 Principia Biopharma Inc. Purinone Derivatives as Tyrosine Kinase Inhibitors
WO2014100065A1 (en) 2012-12-20 2014-06-26 Merck Sharp & Dohme Corp. Substituted imidazopyridines as hdm2 inhibitors
ME03000B (me) 2012-12-21 2018-10-20 Plexxikon Inc Jedinjenja i metode modulacije kinaze i povezane indikacije
US9305578B1 (en) * 2013-08-01 2016-04-05 Seagate Technology Llc Magnetic element with reduced shield-to-shield spacing
SG11201605417QA (en) 2014-02-03 2016-08-30 Cadila Healthcare Ltd Heterocyclic compounds
CN107001362A (zh) 2014-10-06 2017-08-01 默克专利有限公司 用作btk抑制剂的杂芳基化合物及其用途
JP2016094368A (ja) 2014-11-14 2016-05-26 大日本住友製薬株式会社 ベンズイミダゾール化合物の新規結晶、及びその製造方法
WO2016086358A1 (en) 2014-12-02 2016-06-09 Merck Sharp & Dohme Corp. Hydroxymethyl piperidine orexin receptor antagonists
KR20170105021A (ko) 2015-01-28 2017-09-18 아스테라스 세이야쿠 가부시키가이샤 피라진카르복사마이드 화합물의 제조 방법 및 그 합성 중간체
EP3912979B1 (en) 2015-06-03 2026-03-25 Principia Biopharma Inc. Tyrosine kinase inhibitors
CN105753863B (zh) 2015-09-11 2018-07-31 东莞市真兴贝特医药技术有限公司 氧代二氢咪唑并吡啶类化合物及其应用
US10358446B2 (en) 2015-10-14 2019-07-23 Zibo Biopolar Changsheng Pharmaceutical Co., Ltd. Bruton's tyrosine kinase inhibitors
KR102780243B1 (ko) 2015-11-17 2025-03-14 메르크 파텐트 게엠베하 Btk 억제 활성을 갖는 피리미딘 및 피리딘 화합물을 사용하여 다발성 경화증을 치료하는 방법
EP3327134A1 (en) 2016-11-28 2018-05-30 Carsten Korth Method and biomarkers for in vitro diagnosis of mental disorders
US20210113568A1 (en) 2018-04-27 2021-04-22 Ono Pharmaceutical Co., Ltd. PREVENTIVE AND/OR THERAPEUTIC AGENT FOR AUTOIMMUNE DISEASE COMPRISING COMPOUND HAVING Btk INHIBITORY ACTIVITY AS ACTIVE INGREDIENT
CA3168146A1 (en) 2020-01-20 2021-07-29 Genzyme Corporation Therapeutic tyrosine kinase inhibitors for relapsing multiple sclerosis (rms)
CN115867346B (zh) 2020-06-02 2025-03-14 Gb005股份有限公司 激酶抑制剂
WO2022081512A1 (en) 2020-10-12 2022-04-21 Synubi Pharmaceuticals Llc Compositions and methods of treatment of neuroinflammatory diseases with bruton's tyrosine kinase inhibitors
CA3201936A1 (en) 2020-12-10 2022-06-16 Minhua Chen Crystal form of tolebrutinib and preparation method thereof
IL303834A (en) 2020-12-23 2023-08-01 Genzyme Corp 4-amino-3-(4-phenoxyphenyl)-1,3-dihydro-2H-imidazo[4,5-C]pyridin-2-one derivatives and their salts
CN117295735B (zh) 2021-04-23 2026-05-12 杭州领业医药科技有限公司 Tolebrutinib晶型、无定型及其制备方法和用途
CN117412749A (zh) 2021-05-21 2024-01-16 杭州领业医药科技有限公司 Tolebrutinib盐及其晶型、其制备方法、其药物组合物和用途
WO2022257845A1 (zh) 2021-06-11 2022-12-15 苏州科睿思制药有限公司 Tolebrutinib的晶型及其制备方法和用途
IL310975A (en) 2021-09-03 2024-04-01 Novartis Ag LOU064 for the treatment of multiple sclerosis
CA3241687A1 (en) 2021-12-21 2023-06-29 Tim Owens Crystalline forms of (r)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-phenoxyphenyl)-1h-imidazo[4,5-c]pyridin-2(3h)-one and salts thereof
CN119212708A (zh) 2022-05-13 2024-12-27 普林斯匹亚生物制药公司 用于髓鞘少突胶质细胞糖蛋白抗体疾病(mogad)的治疗性酪氨酸激酶抑制剂
EP4540229A1 (en) 2022-06-14 2025-04-23 Principia Biopharma Inc. Methods of making tolebrutinib
US20260022123A1 (en) 2022-06-22 2026-01-22 Principia Biopharma Inc. Methods of Making Modified BTK Inhibitors
CA3260159A1 (en) 2022-06-30 2024-01-04 Principia Biopharma Inc. Therapeutic Tyrosine Kinase Inhibitors for the Treatment of Multiple Sclerosis and Myasthenia Gravis
US20240173313A1 (en) 2022-10-11 2024-05-30 Genzyme Corporation Therapeutic tyrosine kinase inhibitors for multiple sclerosis
US20240238267A1 (en) 2022-12-20 2024-07-18 Genzyme Corporation Drug formulations of (r)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-phenoxyphenyl)-1h-imidazo[4,5-c]pyridin-2(3h)-one
AU2024214470A1 (en) 2023-02-01 2025-09-11 Principia Biopharma Inc. Methods of diagnosing and treating multiple sclerosis by detecting a biomarker in the cerebrospinal fluid
US20250282777A1 (en) 2024-03-06 2025-09-11 Principia Biopharma Inc. Methods of Making Tolebrutinib
WO2026050513A1 (en) 2024-08-30 2026-03-05 Principia Biopharma Inc. Tolebrutinib for multiple sclerosis
US20260060974A1 (en) 2024-08-30 2026-03-05 Principia Biopharma Inc. Therapeutic tyrosine kinase inhibitors for multiple sclerosis

Also Published As

Publication number Publication date
CN116710452A (zh) 2023-09-05
MX2023007641A (es) 2023-07-07
AU2021409575B2 (en) 2026-06-04
AU2021409575A1 (en) 2023-08-10
US20240051955A1 (en) 2024-02-15
KR20230124663A (ko) 2023-08-25
US12624030B2 (en) 2026-05-12
EP4267572A1 (en) 2023-11-01
CN116710452B (zh) 2026-06-05
IL303834A (en) 2023-08-01
CO2023009491A2 (es) 2023-07-31
WO2022140511A1 (en) 2022-06-30
JP2024501247A (ja) 2024-01-11
TW202241887A (zh) 2022-11-01

Similar Documents

Publication Publication Date Title
US12624030B2 (en) 4-amino-3-(4-phenoxyphenyl)-1,3-dihydro-2H-imidazo[4,5-c]pyridin-2-one derivatives and salts thereof
AU2021246147B2 (en) RIP1K inhibitors
US10093656B2 (en) Fused-ring or tricyclic aryl pyrimidine compound used as kinase inhibitor
TWI468402B (zh) 降低β－類澱粉生成之化合物
EP4269405A1 (en) Preparation and application method of heterocyclic compound as kras inhibitor
EP3578561A1 (en) Spiro compounds
JP7558977B2 (ja) メチル基及びトリフルオロメチル基を含む二置換スルファミド系選択的ｂｃｌ－２阻害剤
AU2016274433B2 (en) Positive allosteric modulators of muscarinic M2 receptor
CA3080949C (en) Immunoproteasome inhibitors
EP4574827A1 (en) Nitrogen-containing heterocyclic compounds and pharmaceutically acceptable salts thereof, preparation method therefor, and the use thereof
CA2982493A1 (en) Jak inhibitors
CA2999818C (en) Quinoxaline and pyridopyrazine derivatives as pi3k.beta. inhibitors
EP4034535B1 (en) Aza-quinoline compounds and uses thereof
EP4055013B1 (en) Wdr5 inhibitors and modulators
EP3697781B1 (en) Antagonists of the muscarinic acetylcholine receptor m4
JP2021513519A (ja) ムスカリン性アセチルコリン受容体ｍ４のアンタゴニスト
CA3199786A1 (en) Antagonists of the muscarinic acetylcholine receptor m4
JP2020530451A (ja) ムスカリン性アセチルコリン受容体ｍ４のアンタゴニスト
EP3590944A1 (en) Azetidine derivative
AU2018205277B2 (en) Small molecule inhibitors of neutral sphingomyelinase 2 (nSMase2) for the treatment of neurodegenerative diseases
EP3758696B1 (en) [1,2,4]triazolo[1,5-a]pyrimidine compounds and use in stabilizing microtubules
CN109476643B (zh) 作为jak抑制剂的吡唑基氨基苯并咪唑衍生物
CN116419753B (zh) 作为bcl-2抑制剂的杂环化合物
EA027177B1 (ru) Макролидные производные, их получение и их терапевтическое использование
EP3766883B1 (en) Imidaxopyrolone compound and application thereof

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241204

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241204

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241204

R11 Change to the name of applicant or owner or transfer of ownership requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R11-R127 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TRANSFER RECORDAL REQUEST OR RESPONSE

Effective date: 20250402

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250402

R14 Transfer of ownership recorded

Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R14-R129 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TRANSFER REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250627

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251003

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251003

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20251201

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20251201

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20251201

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260128

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20260128

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20260128

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20260128

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260128

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260129

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260728